Multi-omics analysis identifies DLX4 as a novel biomarker for diagnosis, prognosis, and immune infiltration: from pan-cancer to renal cancer
Our study explored the mechanisms of DLX4 in pan-cancer, especially in renal clear cell carcinoma, identifying it as a promising biomarker and therapeutic target.
Authors
- Shuaizhi Zhu
- Hai Zhu (ORCID: https://orcid.org/0000-0002-0405-1011)
- Shufei Wang (ORCID: https://orcid.org/0000-0001-6248-4520)
- Zengshun Kou
- Jiaxi Zhu
- Zhongzhou Si (ORCID: https://orcid.org/0000-0003-2456-6431)
- Yu Zheng
- Shengjie Zhou (ORCID: https://orcid.org/0000-0002-1657-9702)
Institutions
- Qingdao University (CN)
- University of Toronto (CA)
- Affiliated Hospital of Qingdao University (CN)
- Qingdao Municipal Hospital (CN)
- Qingdao Center of Resource Chemistry and New Materials (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1007/s12672-025-02258-z
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shandong Province